Emami’s Stellar Performance Continues In Q3, Says Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Emami Ltd.’s Q3 FY21 results were ahead of our estimates.
The domestic business jumped 16%, while international business posted 26% revenue growth in Q3.
Barring Navratna range, all other products posted positive growth, demonstrating encouraging performance. Healthcare range maintained strong acceleration with 38% growth.
Emami launched 30 new products during nine months of FY21. New product development contributes 4% of domestic revenues.
The international business posted a 26% growth driven by 8% increase in SAARC and 82% growth in the Middle East, North Africa and Pakistan.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.